BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Proteasome subunit β2 (PSMB2)

...exhibited less liver, spleen and kidney toxicity than paclitaxel alone. Next steps in collaboration with Ramsey Lake Pharma Corp....
...B cell lymphoma. TARGET/MARKER/PATHWAY: Proteasome subunit β2 (PSMB2) LICENSING STATUS: Patent application filed; licensed to Ramsey Lake Pharma...
BioCentury | Aug 24, 2015
Clinical News

Ramsey Lake Pharma preclinical data

...alone. VR23 is a next-generation quinolone-sulfonyl hybrid proteasome inhibitor. Data were published in Cancer Research. Ramsey Lake Pharma Corp....
Items per page:
1 - 2 of 2
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Proteasome subunit β2 (PSMB2)

...exhibited less liver, spleen and kidney toxicity than paclitaxel alone. Next steps in collaboration with Ramsey Lake Pharma Corp....
...B cell lymphoma. TARGET/MARKER/PATHWAY: Proteasome subunit β2 (PSMB2) LICENSING STATUS: Patent application filed; licensed to Ramsey Lake Pharma...
BioCentury | Aug 24, 2015
Clinical News

Ramsey Lake Pharma preclinical data

...alone. VR23 is a next-generation quinolone-sulfonyl hybrid proteasome inhibitor. Data were published in Cancer Research. Ramsey Lake Pharma Corp....
Items per page:
1 - 2 of 2